These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38180395)

  • 1. Cancer Treatment-Related Complications in Patients With Hypertrophic Cardiomyopathy.
    Zampieri M; Schoonvelde SAC; Vinci M; Meattini I; Visani L; Fornaro A; Coppini R; Romei A; Marchi A; Morelli I; van Slegtenhorst MA; Palinkas ED; Livi L; Michels M; Olivotto I
    Mayo Clin Proc; 2024 Feb; 99(2):218-228. PubMed ID: 38180395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.
    Songsirisuk N; Kittipibul V; Methachittiphan N; Charoenattasil V; Zungsontiporn N; Spanuchart I; Buppajarntham S; Mankongpaisarnrung C; Satitthummanid S; Srimahachota S; Chattranukulchai P; Boonyaratavej Songmuang S; Puwanant S
    BMC Cardiovasc Disord; 2019 Jan; 19(1):1. PubMed ID: 30606129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy.
    Killu AM; Park JY; Sara JD; Hodge DO; Gersh BJ; Nishimura RA; Asirvatham SJ; McLeod CJ
    Europace; 2018 Jan; 20(1):82-88. PubMed ID: 29315424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
    Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
    Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.
    Rowin EJ; Maron BJ; Haas TS; Garberich RF; Wang W; Link MS; Maron MS
    J Am Coll Cardiol; 2017 Feb; 69(7):761-773. PubMed ID: 28209216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and outcome of patients with dilated-hypertrophic cardiomyopathy].
    Li PR; Li XL; Xu F; Gou C; Deng MJ; Liu JQ; Wang K
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):327-30. PubMed ID: 27112611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
    Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy.
    Subasic K
    Nurs Clin North Am; 2013 Dec; 48(4):571-84. PubMed ID: 24295188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy in the adolescent.
    Ellims AH
    Aust Fam Physician; 2017; 46(8):553-557. PubMed ID: 28787553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.
    Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS
    Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular evaluation of pregnant women with hypertrophic cardiomyopathy.
    Güner A; Candan Ö; Kahraman S; Güner EG; Özcan S; Gürsoy MO; Kalçık M; Uslu A; Dönmez E; Zehir R; Ertürk M; Yıldız M; Özkan M
    Herz; 2023 Mar; 48(2):141-151. PubMed ID: 35364724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.
    Maron BJ; Casey SA; Poliac LC; Gohman TE; Almquist AK; Aeppli DM
    JAMA; 1999 Feb; 281(7):650-5. PubMed ID: 10029128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden cardiac death: investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort.
    Anastasakis A; Theopistou A; Rigopoulos A; Kotsiopoulou C; Georgopoulos S; Fragakis K; Sevdalis E; Stefanadis C
    Hellenic J Cardiol; 2013; 54(4):281-8. PubMed ID: 23912920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
    Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
    Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.